IRCT201208043799N5 IRCT 2013-01-27 Tehran University of Medical Sciences Vice chancellor for research colchicin and prevention of atrial fibrillation Effects of low dose colchicin in prevention of atrial fibrillation after coronary artery bypass graft (A Placebo-Controlled Randomized Clinical Trial) 2012-10-22 anticipated 216 Complete https://irct.ir/trial/3918 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention. 2 Coronary artery disease. Intervention 1: In the intervention group with systolic blood pressure above 80 mmgh and rate of more than 60/min, a total of 7.0 mg oral Colchicine is administered as: 1.0 mg, the night before surgery and also 1.0 mg, on the morning of surgery and then from the first day after operation followed by a maintenance dose of 0.5 mg, twice a day in patients ≥70 kg and halved dose for patients <70 kg for five days after surgery. Colchicine is an anti-inflammatory medication used to prevent and ease gout attacks. Colchicine is available as oral tablets. Each scored tablet contains 1 mg Colchicine. This product is manufactured by Modava pharmaceutical company. Intervention 2: Patients in the control group receive placebo pills which are specifically designed to have no real effect. They are made of an inert substance. These tablets in terms of size, shape, packaging and name are exactly similar to the colchicin tablets. Only the code written on the boxes are different from each other. Frequency and duration of using placebo pills in the control group are absolutely the same as colchicine pills in the intervention group. This product is manufactured by Modava pharmaceutical company.